Suppliers / Wuhan Biocause Pharmaceutical Development
Wuhan Biocause Pharmaceutical Development
China 3 employees Updated 9 July 2026
Wuhan Biocause Pharmaceutical Development is an API manufacturer based in China. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as VAI.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 14 March 2025 VAI US FDA
- 24 August 2018 VAI US FDA
- 22 July 2016 VAI US FDA
- 28 February 2014 VAI US FDA
- 23 July 2010 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| China, China | 3004202226 |
What they file, and where
| Molecule | Regulators | Docs |
| Azacitidine | SFDA (Saudi Arabia) | 1 |
| Flumazenil | SFDA (Saudi Arabia) | 1 |
| Granisetron | SFDA (Saudi Arabia) | 1 |
| Milrinone | SFDA (Saudi Arabia) | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Wuhan Biocause Pharmaceutical Development comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 14 March 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates